File(s) under permanent embargo
Strontium ranelate, a promising disease modifying osteoarthritis drug
Areas covered: A literature search was performed on PubMed and European Medicines Agency (EMA) website for all publications and documents related to SrR and OA. References of related studies were searched by hand. Treatment with SrR, especially at the dosage of 2 g/day, was associated with reduced radiographic knee OA progression, and with meaningful clinical improvement. It was also significantly associated with decreased MRI-assessed cartilage volume loss (CVL) and bone marrow lesions (BMLs).
Expert opinion: SrR could be a promising DMOAD particularly for OA patients with bone phenotypes. The clinical efficacy and side effects of SrR for OA treatment need to be further investigated in future clinical trials before clinical application.
Publication titleExpert Opinion on Investigational Drugs
Department/SchoolMenzies Institute for Medical Research
PublisherAshley Publications Ltd
Place of publicationUnitec House, 3Rd Fl, 2 Albert Place, Finchley Central, London, England, N3 1Qb
Rights statement© 2017 Informa UK